Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Nvp Healthcare Co. Ltd. maintains 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 2 distinct examiners and 2 distinct art units. The presence of 2 pending office actions suggests a targeted prosecution effort within this specific technical field.
Dennis Ignatius Armato Jr acts as the busiest examiner for the portfolio, currently overseeing 1 pending office action. The presence of 2 distinct examiners across 2 distinct art units suggests that each matter is being reviewed in a unique technical and administrative context. This arrangement requires the company to navigate different examiner perspectives for its 2 pending office actions.
For the 2 pending office actions, the applicant must address the specific concerns of 2 distinct examiners. Since the examiners are located within 2 distinct art units, there may be different prior art or internal guidelines that influence each case. Practitioners should develop tailored strategies for each of the 2 pending office actions to account for the unique requirements of each art unit.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ARMATO JR, DENNIS IGNATIUS | 1 | 42.9% | +80.0% |
| DURYEE, ALEXANDER MARSH | 1 | 33.3% | +41.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18697727 | NOVEL PROBIOTICS AND USE THEREOF | ARMATO JR, DENNIS IGNATIUS | 20d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18027889 | NOVEL LACTIC ACID BACTERIA AND USE THEREOF | DURYEE, ALEXANDER MARSH | 11d overdue |
| 18697727 | NOVEL PROBIOTICS AND USE THEREOF | ARMATO JR, DENNIS IGNATIUS | 20d |
| Art Unit | Apps |
|---|---|
| 1651 | 1 |
| 1657 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18697727 | NOVEL PROBIOTICS AND USE THEREOF | ARMATO JR, DENNIS IGNATIUS | 1651 | §103§112 | Non-Final OA | 20d | Pending | Apr 01, 2024 |
| 18027889 | NOVEL LACTIC ACID BACTERIA AND USE THEREOF | DURYEE, ALEXANDER MARSH | 1657 | §103 | Non-Final OA | 11d overdue | Pending | Mar 22, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNvp Healthcare Co. Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Dennis Ignatius Armato Jr. has the most, with 1 of Nvp Healthcare Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
